Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
Condition(s) studied
Investigational drug(s) / intervention(s)
circulating tumor DNA dosage: blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
Study summary
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Eligibility
Primary outcome measure(s)
- Change in tcNA dosage between baseline and 6 Months — 6 months
evolution of tcDNA percentage between Baseline and at 6 months after surgery - Change in tcDNA dosage between baseline and 3 Months — 3 months
evolution of tcDNA percentage between Baseline and at 3 months after surgery
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu Rouen | Rouen | France | Recruiting |
More University Hospital, Rouen trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05375370 on ClinicalTrials.gov ↗ ← All trials in France